2001
DOI: 10.4049/jimmunol.167.10.5852
|View full text |Cite
|
Sign up to set email alerts
|

A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy

Abstract: Intense efforts of research are made for developing antitumor vaccines that stimulate T cell-mediated immunity. Tumor cells specifically express at their surfaces antigenic peptides presented by MHC class I and recognized by CTL. Tumor antigenic peptides hold promise for the development of novel cancer immunotherapies. However, peptide-based vaccines face two major limitations: the weak immunogenicity of tumor Ags and their low metabolic stability in biological fluids. These two hurdles, for which separate sol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
43
0

Year Published

2004
2004
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 45 publications
(47 citation statements)
references
References 49 publications
(98 reference statements)
1
43
0
Order By: Relevance
“…We asked whether encapsulation into SSL could protect peptides from plasma enzyme degradation, as indirectly measured by comparing their capacity to sensitise target cells to the killing by specific CTL. In agreement with previous reports (Blanchet et al, 2001), M27 -35 peptide was rapidly degraded (80% loss of activity) within 45 min of preincubation in the presence of human plasma. Encapsulation of M27 -35 into SSL appeared to effectively protect the epitope from enzymatic degradation, with loss of activity in those same conditions limited to 30%.…”
Section: Encapsulation Of M27 -35 Peptide Into Ssl Improves Immunorecsupporting
confidence: 93%
See 4 more Smart Citations
“…We asked whether encapsulation into SSL could protect peptides from plasma enzyme degradation, as indirectly measured by comparing their capacity to sensitise target cells to the killing by specific CTL. In agreement with previous reports (Blanchet et al, 2001), M27 -35 peptide was rapidly degraded (80% loss of activity) within 45 min of preincubation in the presence of human plasma. Encapsulation of M27 -35 into SSL appeared to effectively protect the epitope from enzymatic degradation, with loss of activity in those same conditions limited to 30%.…”
Section: Encapsulation Of M27 -35 Peptide Into Ssl Improves Immunorecsupporting
confidence: 93%
“…On the other hand, M26 -35 is known to be more immunogenic that M27 -35 (Valmori et al, 1998) and more resistant to plasma peptidases (Blanchet et al, 2001). In this respect, SSL encapsulation did not provide any further advantage.…”
Section: Discussionmentioning
confidence: 90%
See 3 more Smart Citations